Předmět: |
|
Zdroj: |
Drug Week; 2/16/2024, p441-441, 1p |
Abstrakt: |
A recent report from King's College London discusses the development of hybrid nanovesicles called "hybridosomes" for the oral delivery of RNA therapies. These hybridosomes, which are made from bovine milk extracellular vesicles and liposomes, have shown efficient loading of small interfering RNA (siRNA) cargo and lower cytotoxicity in intestinal cells compared to traditional liposomes. They also exhibit higher stability in simulated intestinal fluid and have the potential to increase the transport of siRNA across the intestinal model. The research concludes that these hybridosomes have the potential to be effective delivery systems for oral RNA therapeutics. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|